AVI BioPharma, Inc. (NASDAQ:AVII)

CAPS Rating: 4 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Recs

0
Player Avatar NEICH (< 20) Submitted: 12/10/2008 11:16:56 AM : Outperform Start Price: $2.50 AVII Score: -59.45

CDSN

Report this Post Reply

Featured Broker Partners


Advertisement